Search Results for “vaccine” – Page 33 – media

BBSRC invests £48m in Babraham Institute to advance lifelong health research

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability to protect health and counter age-related decline, including cellular response to stress, epigenetic control across the life course, immunity, resilience and repair. In close collaboration with partners across academia, including the BBSRC’s other strategically supported research institutes and companies based on the Babraham Research Campus, the research will be delivered ...
- Source: drugdu
- 108
- May 16, 2024
Answering the Call

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients. Yvonne Greenstreet, CEO, Alnylam It’s no surprise that Yvonne Greenstreet is winning awards. On Jan. 9, the Healthcare Businesswomen’s Association (HBA) announced the Alnylam CEO as its 2024 Woman of the Year. In the release, the HBA said that Greenstreet had earned the honor through her “notable and remarkable commitment and valuable contributions to women in the healthcare ecosystem.” It went on to describe Greenstreet as a trailblazer, advocate, and a true leader. Specifically, Greenstreet’s leadership at Alnylam, an RNA interference (RNAi) therapeutics company, was recognized. Since being appointed CEO in October 2021, she has helped steer Alnylam to being named one of Fortune’s Best Workplaces for Women. ...
- Source: drugdu
- 72
- May 14, 2024
Sino Biological concludes SignalChem acquisition for $48m.

Sino Biological has concluded the acquisition of Canadian biotechnology company SignalChem Biotech (SCB) for $48m in a move that expands its product portfolio and strengthens its global presence. The related share purchase agreement was signed between the companies in October 2023. The deal includes all assets and assumed indebtedness, along with net cash deposits, marking a significant expansion for the Shenzhen stock exchange-listed biotech company. Sino Biological president and general manager Dr Jie Zhang stated: “SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies. “The acquisition of SCB further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services.” SignalChem is engaged in developing bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. It is now integrated as a wholly-owned subsidiary of Sino Biological. SCB will offer exclusive ...
- Source: https://www.pharmaceutical-technology.com/news/sino-biological-signalchem-48m/
- 83
- May 4, 2024
“Profound concern” over WHO’s pandemic agreement, says AIDS charity

The AHF Global Public Health Institute has voiced concerns over the World Health Organization’s (WHO) proposed pandemic agreement, saying that the private interest of pharmaceutical companies has taken priority over global health security. The AHF Global Public Health Institute, a joint initiative of the AIDS Healthcare Foundation and the University of Miami, outlined issues in the latest iteration of the text from the WHO via a 26 April press release. The Pandemic Agreement, also known as the pandemic accord, is a proposed international joint initiative to fight the next pathogen that threatens global health. The framework is meant to implement lessons learned from the response to Covid-19 to improve shared response between nations. Member states have a deadline of May 2024 to join the treaty accord. Research indicates that Covid-19 would have caused 40 million more deaths in the absence of preventative measures. Countries have been ...
- Source: https://www.pharmaceutical-technology.com/news/profound-concern-over-whos-pandemic-agreement-says-aids-charity/?cf-view
- 138
- May 4, 2024
KCL study reveals particles in cows’ milk effective for oral delivery of RNA drugs

In a new study, researchers from King’s College London (KCL) have revealed that tiny particles present in cows’ milk could offer a new and effective method for the oral delivery of ribonucleic acid (RNA) drugs. Published in the Journal of Nanobiotechnology, the tiny particles known as extracellular vesicles (EV) could help protect and deliver RNA drugs following oral administration. RNA therapies are a powerful class of drugs based on nucleic acids that offer a way to target previously untreatable diseases on a molecular level. Despite successful administration via injection, there has been no successful way to deliver them orally, as the drugs are destroyed by the harsh conditions of the gut. Researchers extracted EVs from cows’ milk and loaded them with RNA molecules to treat inflammatory bowel disease (IBD). EVs are nanoscale transporters that carry biological molecules in a protective coat throughout the body, controlling and regulating the access of ...
- Source: drugdu
- 107
- May 1, 2024
Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pancreatic cancer. Orphan drug designations are granted to medicines intended to treat rare conditions and come with benefits such as tax credits for US-based clinical trials and potentially seven years of market exclusivity in the designated indication upon agency approval. Pancreatic cancer is one of the most lethal forms of cancer, with a survival rate beyond ten years of around 5%. CAN-2409 was also granted fast track designation in pancreatic cancer by the FDA in December 2023, meaning the candidate is in line for expedited development and review times. CAN-2409 is an off-the-shelf immunotherapy that is a combination of a genetically modified adenovirus and the herpes simplex virus thymidine kinase (HSV-tk) gene. The drug works by inducing T cell response at both the targeted tumour and at ...
- Source: drugdu
- 74
- April 16, 2024
Unitaid funds over £6m to Liverpool researchers to treat major diseases

A research project led by the University of Liverpool has been awarded over £6m by Unitaid, a global health initiative to prevent, diagnose and treat major diseases in low- and middle-income countries (LMICs) and to advance long-acting therapeutics to treat or prevent tuberculosis, malaria and hepatitis C. First launched in 2020, the LONGEVITY project aims to ensure that therapeutics for these conditions are easily accessible in LMICs as part of the University of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT). To date, the project has already accomplished preclinical proof of concept for long-acting medications for tuberculosis, an infectious disease caused by a bacterium that affects the lungs, and a therapy for the hepatitis C virus, which can lead to liver infection. Caused by a parasite transmitted through bites of infected mosquitoes, malaria is responsible for an estimated 247 million cases, according to the World Health Organization’s 2022 World Malaria ...
- Source: drugdu
- 141
- April 10, 2024
CanSinoBio Invited to Boao Forum for Asia 2024 Annual Conference

On the afternoon of March 29, the Boao Forum for Asia (BFA) 2024 Annual Conference came to an end. During the four-day conference, nearly 2,000 Chinese and foreign guests from more than 60 countries and regions focused on the theme of “Asia and the World: Common Challenges, Common Responsibilities”, exchanged views on the world economy, scientific and technological innovation, social development, international cooperation and other issues, and discussed the propositions of the times together. Dr. Xuefeng Yu, Chairman and CEO of CanSinoBio, was invited to attend the forum and discussed with more than 20 medical and health experts, industry think tanks and representatives of innovative enterprises from China, the United Arab Emirates, Kenya, Nigeria, South Africa, Singapore, and India on the theme of “Health without Borders – International Medical and Healthcare Cooperation. Through the development of new quality productivity, strengthen the global cooperation to eliminate health disparities and promote global ...
- Source: drugdu
- 138
- April 4, 2024
Minhai Biotech Signs Strategic Cooperation Memorandum with Daxing District Government and AstraZeneca

On March 25th, Daxing District Government, AstraZeneca, Minhai Biological and other companies signed a strategic cooperation memorandum in Daxing, Beijing, to jointly explore the mode of cooperation in the field of vaccines, and help China’s vaccine innovation products to cooperate and develop at home and abroad. Daxing District’s life and health industry ecosystem has been continuously improved, creating a favorable business environment that attracts foreign investment and strengthens the confidence of global outstanding enterprises in long-term development in Beijing. The strategic cooperation between AstraZeneca and Minhai Biotechnology will further expand the circle of friends and influence of Daxing District’s world-class vaccine industry cluster, and will become a substantive measure for Daxing District to implement the “Action Plan for Attracting and Utilizing Foreign Investments with Greater Efforts by Solidly Pushing Forward the Opening Up of the Country to the Outside World at a High Level”. This time in Beijing Daxing to ...
- Source: drugdu
- 136
- March 30, 2024
FDA Approves Roche’s Cobas Malaria Test, Designed to Screen for Malaria in Potential Blood Donors

Don Tracy, Associate Editor Action marks the first FDA-approved blood screening test for malaria. Roche announced that the FDA has officially approved the Cobas Malaria test, focused on inspecting blood donors for malaria, aiming to enhance the safety of blood supply. The test, which screens blood samples for five species of Plasmodium parasites, is the first of its kind approved for this purpose and aims to reduce the risk of malaria transmission through transfusions. Roche stated that it expects the test to be available in the United States at some point during the second quarter of this year.1 “As the first FDA-approved blood screening test for malaria, this represents an important step forward in safeguarding the global supply of donated blood,” said Matt Sause, CEO, Roche Diagnostics, in a press release. “The approval of cobas Malaria represents a significant advancement in malaria detection, offering healthcare professionals a reliable tool for ...
- Source: drugdu
- 142
- March 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.